Abstract Background Patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) treated with pralatrexate have previously shown superior overall survival (OS) compared to those who underwent conventional chemotherapy (CC. 15. 4 vs. 4. https://www.pomyslnaszycie.com/white-and-green-bulletin-board-border-simply-boho-schoolgirl-style-on-sale/